Avecho Receives AU$1.98 Million R&D Tax Incentive to Support CBD Insomnia Program and Commercial Expansion
Avecho Biotechnology Limited (ASX: AVE) has received approximately AU$1.98 million under the Australian Government’s Research & Development Tax Incentive Scheme for the year ended 31 December 2025, strengthening the Company’s funding position as it advances its cannabinoid-based pharmaceutical development strategy.
The proceeds will be used to repay AU$1.62 million advanced by Endpoint Capital against the Company’s anticipated tax credit, while also supporting ongoing operations and commercialization initiatives. Avecho noted that the funding reinforces its commitment to developing differentiated cannabinoid formulations utilising its proprietary Tocopheryl Phosphate Mixture (TPM®) drug delivery platform.
The Company’s primary asset, a CBD-based TPM soft-gel capsule targeting insomnia, is advancing through a pivotal Phase III study being conducted at multiple sites across Australia. Management highlighted that the study has been designed to meet requirements of the TGA, FDA and EMA, supporting a potential pathway toward pharmaceutical registration and over-the-counter commercialization opportunities in Australia.
Avecho also noted that insomnia remains a major global healthcare issue, with the broader sleep economy and sleep aid market projected to reach approximately US$950 billion by 2032.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Avecho Receives AU$1.98 Million R&D Tax Incentive to Support CBD Insomnia Program and Commercial Expansion
Avecho Biotechnology Limited (ASX: AVE) has received approximately AU$1.98 million under the Australian Government’s Research & Development Tax Incentive Scheme for the year ended 31 December 2025, strengthening the Company’s funding position as it advances its cannabinoid-based pharmaceutical development strategy.
The proceeds will be used to repay AU$1.62 million advanced by Endpoint Capital against the Company’s anticipated tax credit, while also supporting ongoing operations and commercialization initiatives. Avecho noted that the funding reinforces its commitment to developing differentiated cannabinoid formulations utilising its proprietary Tocopheryl Phosphate Mixture (TPM®) drug delivery platform.
The Company’s primary asset, a CBD-based TPM soft-gel capsule targeting insomnia, is advancing through a pivotal Phase III study being conducted at multiple sites across Australia. Management highlighted that the study has been designed to meet requirements of the TGA, FDA and EMA, supporting a potential pathway toward pharmaceutical registration and over-the-counter commercialization opportunities in Australia.
Avecho also noted that insomnia remains a major global healthcare issue, with the broader sleep economy and sleep aid market projected to reach approximately US$950 billion by 2032.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au